# Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

> **NCT02692742** · PHASE2 · COMPLETED · sponsor: **Myelo Therapeutics GmbH** · enrollment: 137 (actual)

## Conditions studied

- Chemotherapy-Induced Neutropenia
- Myelosuppression
- Breast Cancer

## Interventions

- **DRUG:** Myelo001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02692742
- **Lead sponsor:** Myelo Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2017-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02692742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02692742, "Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02692742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*